公开(公告)号：EP1629013B1

公开(公告)日：2018-01-24

申请号：EP04734816.4

申请日：2004-05-26

申请人： Amgen Research (Munich) GmbH

发明人： KUFER, Peter ,  BERRY, Meera ,  OFFNER, Sonja ,  BRISCHWEIN, Klaus ,  WOLF, Andreas ,  RAUM, Tobias ,  KOHLEISEN, Birgit ,  LENKKERI-SCHÜTZ, Ulla ,  BÄUERLE, Patrick

IPC分类号： C07K16/30 ,  C07K16/28 ,  A61K39/395

CPC分类号： C07K16/30 ,  A61K2039/505 ,  C07K16/2809 ,  C07K16/3076 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2319/00 ,  Y10S435/81 ,  Y10S435/975

摘要： The present invention provides a pharmaceutical composition comprising a bispecific single chain antibody construct. Said bispecific single chain antibody construct is characterized to comprise or consist of at least two domains, whereby one of said at least two domains specifically binds to human EpCAM and comprises at least one CDR-H3 region comprising the amino acid sequence NXID antigen and a second domain binds to human CD3 antigen. The invention further provides a process for the production of the pharmaceutical composition of the invention, a method for the prevention, treatment or amelioration of a tumorous disease and the use of the disclosed bispecific single chain antibody construct and corresponding means in the prevention, treatment or amelioration of a tumorous disease.

公开(公告)号：EP1629012B1

公开(公告)日：2018-11-28

申请号：EP04739378.0

申请日：2004-05-26

申请人： Amgen Research (Munich) GmbH

发明人： KUFER, Peter ,  LUTTERBÜSE, Ralf ,  KOHLEISEN, Birgit ,  ZEMAN, Steven ,  BÄUERLE, Patrick

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61P35/02 ,  A61P19/02

CPC分类号： C07K16/2803 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/622

摘要： The present invention relates to a pharmaceutical composition comprising a bispecific single chain antibody construct comprising binding domains specific for human CD3 and human CD19, wherein the corresponding variable heavy chain regions (VH) and the corresponding variable light chain regions (VL) regions are arranged, from N-terminus to C-terminus, in the order VH(CD19)-VL(CD19)-VH(CD3)-VL(CD3) or VH(CD3)-VL-(CD3)-VH(CD19)-VL (CD19). Processes for the production of the pharmaceutical compositions and medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CD19 antigen are also disclosed.